Fisetin Bioavailability Limitations: Research Overview

The gap between cell culture effective concentrations (10-100 μM) and achievable human plasma levels (low μM to nM) undermines the translational relevance of much preclinical evidence. Oral bioavailability is estimated at less than 10%.

Fisetin's oral bioavailability is estimated at less than 10% due to poor aqueous solubility (~10.45 μg/mL), extensive first-pass metabolism, and rapid systemic clearance with a 1-3 hour half-life.

Liposomal and nanoparticle formulations show 3-10× improved bioavailability in animal models, but no enhanced formulation has been validated in a human clinical efficacy trial as of 2026.

Fisetin undergoes extensive first-pass metabolism (glucuronidation, sulfation, methylation) in the intestinal epithelium and liver. Over 90% of an oral dose is not absorbed, metabolized before reaching circulation, or rapidly eliminated.

Whether metabolites (geraldol, fisetin-glucuronides, sulfated conjugates) retain senolytic or anti-inflammatory activity is poorly studied. This adds uncertainty rather than confidence to fisetin research.

BCS Class IV compounds have low solubility and low permeability — the most challenging category for oral drug delivery. Fisetin falls in this class due to poor aqueous solubility (~10.45 μg/mL).

No specific food-effect studies have been published for fisetin. Fat may theoretically improve absorption of lipophilic compounds, but this has not been validated for fisetin.

Liposomal fisetin encloses fisetin within phospholipid bilayers, protecting it from degradation. Animal studies show 3-5× improved bioavailability, but human efficacy validation is lacking.

Both have poor oral bioavailability (<10%). Fisetin's bioavailability is comparable to or worse than curcumin. Both are BCS Class IV compounds requiring enhanced formulations.

In rat studies, oral fisetin (50 mg/kg) produced peak plasma concentrations of approximately 2-5 μM — at the lower end of the 10-20 μM range shown to be senolytic in cell culture.

Piperine may inhibit glucuronidation enzymes (as with curcumin), but this has not been specifically validated for fisetin. The effect on fisetin bioavailability is theoretical.

Injectable fisetin bypasses first-pass metabolism and has been used in animal research, but it is not available for human use. IV administration would achieve higher plasma concentrations.

Higher price does not guarantee better bioavailability. No enhanced formulation has been validated in human clinical trials for improved efficacy. Commercial claims of 'enhanced bioavailability' are often not supported by published evidence.

Fisetin's estimated plasma half-life is 1-3 hours, meaning rapid systemic clearance after oral dosing. This short half-life further limits tissue exposure.

Nanoparticle delivery systems (PLGA, chitosan, solid lipid nanoparticles) showed 4-10× improved bioavailability in rodent models. Human pharmacokinetic validation is needed before conclusions can be drawn.